Skip to content
value.today

Zymeworks Inc.: peers

Change the peers

Zymeworks Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Bellus Health, Cybin D/B/A Helus Pharma, Trillium Therapeutics, Agios Pharmaceuticals, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Zymeworks Inc., Aurinia Pharmaceuticals Inc., Xenon Pharmaceuticals Inc., AbCellera Biologics Inc., Bellus Health, Cybin D/B/A Helus Pharma, Trillium Therapeutics, Agios Pharmaceuticals, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureZymeworks Inc.base
ZYME · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Aurinia Pharmaceuticals Inc.
AUPH · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Xenon Pharmaceuticals Inc.
XENE · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
AbCellera Biologics Inc.
ABCL · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Bellus Health
BHN0.F · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Cybin D/B/A Helus Pharma
HELP · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Trillium Therapeutics
TRIL · 🇨🇦 CA
Percentile in Healthcare
Percentile in Canada
Agios Pharmaceuticals, Inc.
AGIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$2.0 BOct 29, 2026 · Market data5th of 8$2.3 BOct 28, 2026 · Market data3rd of 8$3.5 BOct 26, 2026 · Market data2nd of 8$4.5 BOct 29, 2026 · Market data1st of 8$1.9 Blast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8$743 MAug 1, 2026 · Market data8th of 8$1.5 Blast known, Jan 1, 2021 · Market dataLast known value: no current one7th of 8$2.0 BAug 1, 2026 · Market data4th of 8$2.0 B8 ranked
Revenue (Better neither way: ranked highest first)$106 MFY2025 · SEC2nd of 5$283 MFY2025 · SEC1st of 5$8 MFY2025 · SEC5th of 5$75 MFY2025 · SEC3rd of 5——————$54 MFY2025 · SEC4th of 5$75 M5 ranked
Net income (Higher is better)$-81 MFY2025 · SEC2nd of 6$287 MFY2025 · SEC1st of 6$-346 MFY2025 · SEC5th of 6$-146 MFY2025 · SEC4th of 6——$-81 MFY2024 · SEC3rd of 6——$-413 MFY2025 · SEC6th of 6$-114 M6 ranked
Employees (Better neither way: ranked highest first)————370December 31, 2025 · Profile2nd of 3174As on 2020 · Profile3rd of 3——————392As on 2021 · Profile1st of 33703 ranked
Growth
Market cap change, 30 days (Higher is better)+10.3%30 days to Oct 29, 2026 · Market data1st of 2————-1.0%30 days to Oct 29, 2026 · Market data2nd of 2————————+4.6%2 ranked
Revenue growth (Higher is better)+38.9%FY2025 · SEC3rd of 481st81st+20.4%FY2025 · SEC4th of 470th69th————+160.6%FY2025 · SEC1st of 495th97th————————————+48.0%FY2025 · SEC2nd of 483rd91st+43.5%4 ranked
Revenue growth, 3 years a year (Higher is better)-36.4%FY2025 · SEC3rd of 42nd2nd+28.3%FY2025 · SEC2nd of 480th87th————-46.3%FY2025 · SEC4th of 42nd1st————————————+56.0%FY2025 · SEC1st of 490th96th-4.1%4 ranked
Margins and returns
Gross margin (Higher is better)————88.5%FY2025 · SEC1st of 290th99th————————————————————88.3%FY2025 · SEC2nd of 290th96th88.4%2 ranked
Operating margin (Higher is better)-87.3%FY2025 · SEC2nd of 425th9th37.1%FY2025 · SEC1st of 497th86th————-289.0%FY2025 · SEC3rd of 412th3rd————————————-873.8%FY2025 · SEC4th of 41st0th-188.2%4 ranked
Net margin (Higher is better)-76.6%FY2025 · SEC2nd of 426th8th101.5%FY2025 · SEC1st of 499th100th————-194.9%FY2025 · SEC3rd of 415th5th————————————-764.0%FY2025 · SEC4th of 42nd1st-135.7%4 ranked
Free cash flow margin (Higher is better)-32.6%FY2025 · SEC1st of 332nd15th————————-231.7%FY2025 · SEC2nd of 314th5th————————————-698.3%FY2025 · SEC3rd of 33rd1st-231.7%3 ranked
Return on equity (Higher is better)-26.7%FY2025 · SEC3rd of 656th30th59.9%FY2025 · SEC1st of 697th98th-51.8%FY2025 · SEC6th of 643rd19th-14.5%FY2025 · SEC2nd of 664th38th————-42.8%FY2024 · SEC5th of 647th23rd————-30.2%FY2025 · SEC4th of 654th24th-28.5%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————7.4×price Oct 28, 2026 · Market dataonly one with it9th19th————————————————————————7.4×—
Price to sales (Better neither way: ranked highest first)18.8×price Oct 29, 2026 · Market data3rd of 482nd93rd7.2×price Oct 28, 2026 · Market data4th of 466th83rd463.1×price Oct 26, 2026 · Market data1st of 498th100th65.7×price Oct 29, 2026 · Market data2nd of 492nd97th————————————37.1×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price42.2×4 ranked
Price to book (Better neither way: ranked highest first)7.4×price Oct 29, 2026 · Market data1st of 478th90th4.0×price Oct 28, 2026 · Market data4th of 460th74th6.0×price Oct 26, 2026 · Market data2nd of 472nd85th4.6×price Oct 29, 2026 · Market data3rd of 464th79th————4.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————1.7×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price5.3×4 ranked
Free cash flow yield (Higher is better)-1.7%price Oct 29, 2026 · Market data1st of 462nd42nd-1.8%price Oct 28, 2026 · Market data2nd of 462nd41st-8.1%price Oct 26, 2026 · Market data4th of 446th24th-3.9%price Oct 29, 2026 · Market data3rd of 456th37th————-6.9%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-18.8%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-2.8%4 ranked
Scorecard
Scorecard (Higher is better)5 of 22FY2025 · Scorecard3rd of 617 of 21FY2025 · Scorecard1st of 63 of 14FY2025 · Scorecard4th of 64 of 20FY2025 · Scorecard5th of 6——1 of 5FY2024 · Scorecard5th of 6——7 of 14FY2025 · Scorecard2nd of 622% passed6 ranked
Valuation checks (Higher is better)0 of 5FY2025 · Scorecard2nd of 43 of 5FY2025 · Scorecard1st of 40 of 5FY2025 · Scorecard2nd of 40 of 5FY2025 · Scorecard2nd of 4————————0% passed4 ranked
Growth checks (Higher is better)2 of 6FY2025 · Scorecard3rd of 56 of 6FY2025 · Scorecard1st of 50 of 2FY2025 · Scorecard5th of 51 of 6FY2025 · Scorecard4th of 5——————3 of 5FY2025 · Scorecard2nd of 533% passed5 ranked
Profitability checks (Higher is better)0 of 5FY2025 · Scorecard3rd of 64 of 5FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard3rd of 60 of 5FY2025 · Scorecard3rd of 6——0 of 3FY2024 · Scorecard3rd of 6——1 of 5FY2025 · Scorecard2nd of 60% passed6 ranked
Financial health checks (Higher is better)2 of 3FY2025 · Scorecard1st of 62 of 3FY2025 · Scorecard1st of 62 of 3FY2025 · Scorecard1st of 62 of 3FY2025 · Scorecard1st of 6——1 of 2FY2024 · Scorecard6th of 6——2 of 3FY2025 · Scorecard1st of 667% passed6 ranked
Shareholder returns checks (Higher is better)1 of 3FY2025 · Scorecard5th of 52 of 2FY2025 · Scorecard1st of 51 of 1FY2025 · Scorecard1st of 51 of 1FY2025 · Scorecard1st of 5——————1 of 1FY2025 · Scorecard1st of 5100% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)99.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 659.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6103.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 640.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6——31.4%2026-Q2 · 13F6th of 6——112.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 679.3%6 ranked
Institutions holding (Better neither way: ranked highest first)2032026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 62762026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 62862026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 61642026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6——1002026-Q2 · 13F6th of 6——2432026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 62236 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+2.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 5+3.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 5+0.6 pp2026-Q2 against 2026-Q1 · 13F4th of 5-2.8 pp2026-Q2 against 2026-Q1 · 13F5th of 5——————+4.7 pp2026-Q2 against 2026-Q1 · 13F1st of 5+2.8 pp5 ranked
Dividends
Shareholder yield (Higher is better)2.1%FY2025 · SEC2nd of 249th52nd4.3%FY2025 · SEC1st of 272nd72nd————————————————————————3.2%2 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Zymeworks Inc.: How market caps are worked out; Aurinia Pharmaceuticals Inc.: How market caps are worked out; Xenon Pharmaceuticals Inc.: How market caps are worked out; AbCellera Biologics Inc.: How market caps are worked out; Bellus Health: How market caps are worked out; Cybin D/B/A Helus Pharma: How market caps are worked out; Trillium Therapeutics: How market caps are worked out; Agios Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Zymeworks Inc.-87.3%FY2025
25th percentile in Healthcaremedian -7.7%, 674 companies
9th percentile in Canadamedian 8.7%, 114 companies
Aurinia Pharmaceuticals Inc.37.1%FY2025
97th percentile in Healthcaremedian -7.7%, 674 companies
86th percentile in Canadamedian 8.7%, 114 companies
Xenon Pharmaceuticals Inc.———
AbCellera Biologics Inc.-289.0%FY2025
12th percentile in Healthcaremedian -7.7%, 674 companies
3rd percentile in Canadamedian 8.7%, 114 companies
Bellus Health———
Cybin D/B/A Helus Pharma———
Trillium Therapeutics———
Agios Pharmaceuticals, Inc.-873.8%FY2025
1st percentile in Healthcaremedian -7.7%, 674 companies
0th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$121 M$243 M$364 M$485 M2012201420162018202020222024Zymeworks Inc. $106 MAurinia Pharmaceuticals Inc. $283 MXenon Pharmaceuticals Inc. $8 MAbCellera Biologics Inc. $75 MAgios Pharmaceuticals, Inc. $54 M

Rank in the group

1st2nd3rd4th5th20122013201420152016201720182019202020212022202320242025Zymeworks Inc.: 3rd of 5 in 2020Zymeworks Inc.: 3rd of 4 in 2021Zymeworks Inc.: 2nd of 5 in 2022Zymeworks Inc.: 2nd of 4 in 2023Zymeworks Inc.: 2nd of 4 in 2024Zymeworks Inc.: 2nd of 5 in 2025Zymeworks Inc.Aurinia Pharmaceuticals Inc.: 3rd of 3 in 2016Aurinia Pharmaceuticals Inc.: 2nd of 3 in 2017Aurinia Pharmaceuticals Inc.: 2nd of 2 in 2018Aurinia Pharmaceuticals Inc.: 4th of 4 in 2019Aurinia Pharmaceuticals Inc.: 2nd of 5 in 2020Aurinia Pharmaceuticals Inc.: 2nd of 4 in 2021Aurinia Pharmaceuticals Inc.: 3rd of 5 in 2022Aurinia Pharmaceuticals Inc.: 1st of 4 in 2023Aurinia Pharmaceuticals Inc.: 1st of 4 in 2024Aurinia Pharmaceuticals Inc.: 1st of 5 in 2025Aurinia Pharmaceuticals InXenon Pharmaceuticals Inc.: 2nd of 2 in 2012Xenon Pharmaceuticals Inc.: 1st of 2 in 2013Xenon Pharmaceuticals Inc.: 2nd of 2 in 2014Xenon Pharmaceuticals Inc.: 2nd of 2 in 2015Xenon Pharmaceuticals Inc.: 2nd of 3 in 2016Xenon Pharmaceuticals Inc.: 3rd of 3 in 2017Xenon Pharmaceuticals Inc.: 3rd of 4 in 2019Xenon Pharmaceuticals Inc.: 4th of 5 in 2020Xenon Pharmaceuticals Inc.: 4th of 4 in 2021Xenon Pharmaceuticals Inc.: 5th of 5 in 2022Xenon Pharmaceuticals Inc.: 5th of 5 in 2025Xenon Pharmaceuticals Inc.AbCellera Biologics Inc.: 2nd of 4 in 2019AbCellera Biologics Inc.: 1st of 5 in 2020AbCellera Biologics Inc.: 1st of 4 in 2021AbCellera Biologics Inc.: 1st of 5 in 2022AbCellera Biologics Inc.: 3rd of 4 in 2023AbCellera Biologics Inc.: 4th of 4 in 2024AbCellera Biologics Inc.: 3rd of 5 in 2025AbCellera Biologics Inc.Cybin D/B/A Helus Pharma: 5th of 5 in 2020Cybin D/B/A Helus PharmaAgios Pharmaceuticals, Inc.: 1st of 2 in 2012Agios Pharmaceuticals, Inc.: 2nd of 2 in 2013Agios Pharmaceuticals, Inc.: 1st of 2 in 2014Agios Pharmaceuticals, Inc.: 1st of 2 in 2015Agios Pharmaceuticals, Inc.: 1st of 3 in 2016Agios Pharmaceuticals, Inc.: 1st of 3 in 2017Agios Pharmaceuticals, Inc.: 1st of 2 in 2018Agios Pharmaceuticals, Inc.: 1st of 4 in 2019Agios Pharmaceuticals, Inc.: 4th of 5 in 2022Agios Pharmaceuticals, Inc.: 4th of 4 in 2023Agios Pharmaceuticals, Inc.: 3rd of 4 in 2024Agios Pharmaceuticals, Inc.: 4th of 5 in 2025Agios Pharmaceuticals, Inc
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearZymeworks Inc.Aurinia Pharmaceuticals Inc.Xenon Pharmaceuticals Inc.AbCellera Biologics Inc.Bellus HealthCybin D/B/A Helus PharmaTrillium TherapeuticsAgios Pharmaceuticals, Inc.
2025$106 MSEC2nd$283 MSEC1st$8 MSEC5th$75 MSEC3rd———$54 MSEC4th
2024$76 MSEC2nd$235 MSEC1st—$29 MSEC4th———$37 MSEC3rd
2023$76 MSEC2nd$176 MSEC1st—$38 MSEC3rd———$27 MSEC4th
2022$412 MSEC2nd$134 MSEC3rd$9 MSEC5th$485 MSEC1st———$14 MSEC4th
2021$27 MSEC3rd$46 MSEC2nd$18 MSEC4th$375 MSEC1st————
2020$39 MSEC3rd$50 MSEC2nd$32 MSEC4th$233 MSEC1st—$1 MSEC5th——
2019—$0 MSEC4th$7 MSEC3rd$12 MSEC2nd———$118 MSEC1st
2018—$0 MSEC2nd—————$94 MSEC1st
2017—$0 MSEC2nd$0 MSEC3rd————$43 MSEC1st
2016—$0 MSEC3rd$2 MSEC2nd————$70 MSEC1st
2015——$16 MSEC2nd————$59 MSEC1st
2014——$28 MSEC2nd————$65 MSEC1st

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Zymeworks Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Aurinia Pharmaceuticals Inc.AUPH · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $2.3 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on file
    Market cap $2.3 B (Oct 28, 2026) · revenue $283 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Xenon Pharmaceuticals Inc.XENE · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $3.5 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on file
    Market cap $3.5 B (Oct 26, 2026) · revenue $8 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • AbCellera Biologics Inc.ABCL · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $4.5 B market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on file
    Market cap $4.5 B (Oct 29, 2026) · revenue $75 M (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Bellus HealthBHN0.F · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $1.9 B market cap against $2.0 B · Same country: Canada
    Market cap $1.9 B (last known, Jul 30, 2023)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    In the group
  • Cybin D/B/A Helus PharmaHELP · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $743 M market cap against $2.0 B · Same country: Canada · Ratios of the last two fiscal years on file
    Market cap $743 M (Aug 1, 2026)
    94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)
    In the group
  • Trillium TherapeuticsTRIL · 🇨🇦 Canada
    Same industry: Biotechnology · Similar size: $1.5 B market cap against $2.0 B · Same country: Canada
    Market cap $1.5 B (last known, Jan 1, 2021) · revenue $0 M (year to December 2020)
    93 of 100 (industry or sector 50 + size 28 + country 15)
    In the group
  • Agios Pharmaceuticals, Inc.AGIO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.0 B (Aug 1, 2026) · revenue $54 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    In the group
  • Vir Biotechnology, Inc.VIR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.0 B (Oct 28, 2026) · revenue $69 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    + Add
  • Generate Biomedicines, Inc.GENB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.0 B (Oct 30, 2026)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    + Add
  • Zenas BioPharma, Inc.ZBIO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.0 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.0 B (Oct 30, 2026) · revenue $10 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    + Add
  • SELLAS Life Sciences Group, Inc.SLS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.1 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.1 B (Oct 30, 2026)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    + Add
  • Vericel CorporationVCEL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $2.1 B market cap against $2.0 B · Same region: Northern America · Ratios of the last two fiscal years on file
    Market cap $2.1 B (Oct 21, 2026) · revenue $276 M (year to December 2025)
    92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.